Likewise, MYC-driven SCLC demonstrates increased sensitivity to arginine deprivation and mTOR inhibition, particularly in combination with checkpoint kinase 1 (CHK1) inhibitors [43,77]. The gene discussed is MYC; the disease is small cell lung carcinoma.